NCT01329354

Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy

Conditions: Non-Hodgkin Lymphoma
Sponsors: Clinica Universidad de Navarra, Universidad de Navarra
Phase: II 

NCT00510471

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Conditions: Non-Hodgkin's Lymphoma
Sponsors: Genitope Corporation
Phase II

NCT00324831

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Conditions: Lymphoma
Sponsors: Favrille
Phase III

NCT00282308

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

Conditions: Rheumatoid Arthritis
Sponsors: Genentech
Phase II

NCT00258336

Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Conditions: Lymphoma 
Sponsors: Favrille
Phase II

2004-004774-85

A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens

Conditions: Non-Hodgkin’s Lymphoma
Sponsors: Biogen Idec Inc
Phase n/a

NCT00090038

Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma

Conditions: Non-Hodgkin's Lymphoma
Sponsors: Biogen Idec
Phase IV

NCT00089115

Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Conditions: Lymphoma
Sponsors: Favrille
Phase III

NCT00071955

Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma

Conditions: Lymphoma
Sponsors: Genitope Corporation
Phase II

NCT00060164

Rituximab, Autologous Vaccine Therapy, and Sargramostim in Treating Patients With Recurrent or Refractory Follicular B-Cell Lymphoma

Conditions:  Lymphoma
Sponsors:  Univeristy Hospitals Seidman Cancer Center, National Cancer Institute (NCI)
Phase II